A Commercialization Model Developed for Oncology and Hematology
Traditionally, manufacturers preparing to launch had three commercialization options: sell, out-license or launch on their own. However, these options may not be ideal for new oncology therapies. Similar to the way contract research organizations disrupted the market in the ’90s before becoming an industry staple, EVERSANA’s fourth commercialization option is the next phase of evolution for pharma.
EVERSANA ONCOLOGY Commercialization is the optimal solution for oncology and hematology drug manufacturers. Through our award-winning commercialization model and innovative cancer drug launch strategy, our partners optimize their investments, minimize risk and increase speed to market.